 |
Athina Kilpelainen is now working as a postdoctoral researcher at the IrsiCaixa AIDS Research Institute in Barcelona, Spain, with much of her work shifting to focus on studying SARS-CoV-2 T-cell immunology in response to the pandemic. ‘[From EAVI2020] I have learned the value of networking and learning from others in the field, both students and PIs alike. I plan to continue working in research, learning, and hopefully contributing to the scientific community as much as I can.’ Read Athina’s original feature. |
 |
Philipp Mundsperger is finishing his PhD and continuing to work at Polymun Scientific, Austria in the field of recombinant protein production. ‘Working with such a great group [EAVI2020] shows once again that collaboration and team spirit are inevitable tools to success. When I try to picture my future self, I’d like to see someone still being curious about nature and being passionate about what he does. But, on the short run, I’ll try to keep it simple and finish my PhD first!’ Read Philipp’s original feature. |
 |
Narcis Saubi (VHIR) is starting a new project to see if human recombinant BCG immunogenicity can be tested in non-human primates while exploring new options in vaccine R&D. ‘Working at EAVI2020 consortium has strongly confirmed how important it is to establish networks. To be part of a group where there are experts in so many different fields, and with such amazing expertise, makes you feel under the scope… The [future] plans are finding a place where to go to work with all the illusion every morning, where to feel the excitement for the new results, and to come back home proud of what I’ve done.’ Read Narcis’ original feature. |
 |
After completing his Ph.D., Yoann Aldon had the opportunity to start a postdoc in Prof Rogier Sanders’ group in Amsterdam focussing on germline-targeting vaccine strategies for HIV-1, while also responding to the pandemic ‘our efforts have been steered away from HIV for a while… and a great amount of work has been and still is being achieved as a scientific community to better understand immune responses to SARS-CoV-2 and the virus’ evolution.” Read Yoann’s original feature. |
 |
Dominik Damm at University Hospital in Erlangen, Germany, hopes to complete his cumulative PhD thesis at the end of 2021, and has recently submitted his second first-author paper. ‘In parallel, I am preparing a fellowship application to go abroad as a postdoc. Since I would like to stay in the field of HIV vaccine research, the EAVI2020 program helped me to build a network of collaboration partners, mentors, and advisors, which may promote my prospect of getting a grant or fellowship.’ Read Dominik’s original feature. |